Christopher Pieczonka

1.8k total citations · 1 hit paper
69 papers, 679 citations indexed

About

Christopher Pieczonka is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Christopher Pieczonka has authored 69 papers receiving a total of 679 indexed citations (citations by other indexed papers that have themselves been cited), including 57 papers in Pulmonary and Respiratory Medicine, 31 papers in Oncology and 23 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Christopher Pieczonka's work include Prostate Cancer Treatment and Research (57 papers), Radiopharmaceutical Chemistry and Applications (23 papers) and Cancer Immunotherapy and Biomarkers (18 papers). Christopher Pieczonka is often cited by papers focused on Prostate Cancer Treatment and Research (57 papers), Radiopharmaceutical Chemistry and Applications (23 papers) and Cancer Immunotherapy and Biomarkers (18 papers). Christopher Pieczonka collaborates with scholars based in United States, Canada and United Kingdom. Christopher Pieczonka's co-authors include Neal D. Shore, Lawrence I. Karsh, Noel A. Armenakas, Duncan J. Summerton, Allen F. Morey, Charles L. Secrest, David A. Hochberg, Jack W. McAninch, Paige White and K. Miller and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Clinical Cancer Research.

In The Last Decade

Christopher Pieczonka

58 papers receiving 663 citations

Hit Papers

Improved Outcomes with Enzalutamide in Biochemically Recu... 2023 2026 2024 2025 2023 25 50 75 100
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Improved Outcomes with Enzalutamide in Biochemically Recurrent Prostate Cancer
    2023 114 citations Stephen J. Freedland, Murilo Luz et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Christopher Pieczonka United States 12 433 142 136 122 111 69 679
F. Gómez-Veiga Spain 14 707 1.6× 188 1.3× 159 1.2× 62 0.5× 155 1.4× 81 899
A. De La Taille France 13 533 1.2× 142 1.0× 95 0.7× 114 0.9× 60 0.5× 56 724
P. Cathcart United Kingdom 9 241 0.6× 167 1.2× 235 1.7× 98 0.8× 45 0.4× 34 613
Roger Paul Germany 15 309 0.7× 200 1.4× 85 0.6× 98 0.8× 51 0.5× 23 567
Peter Hammerer Germany 15 478 1.1× 155 1.1× 176 1.3× 140 1.1× 81 0.7× 52 868
Henriette Lindberg Denmark 14 268 0.6× 145 1.0× 167 1.2× 25 0.2× 122 1.1× 40 599
Brian Chon United States 14 187 0.4× 95 0.7× 74 0.5× 16 0.1× 205 1.8× 36 797
Samuel Huang United States 9 150 0.3× 133 0.9× 168 1.2× 44 0.4× 21 0.2× 14 412
Se Joong Kim South Korea 13 257 0.6× 66 0.5× 107 0.8× 87 0.7× 19 0.2× 43 444
Muhammad Bulbul Lebanon 12 279 0.6× 212 1.5× 71 0.5× 66 0.5× 15 0.1× 52 481

Countries citing papers authored by Christopher Pieczonka

Since Specialization
Citations

This map shows the geographic impact of Christopher Pieczonka's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Christopher Pieczonka with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Christopher Pieczonka more than expected).

Fields of papers citing papers by Christopher Pieczonka

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Christopher Pieczonka. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Christopher Pieczonka. The network helps show where Christopher Pieczonka may publish in the future.

Co-authorship network of co-authors of Christopher Pieczonka

This figure shows the co-authorship network connecting the top 25 collaborators of Christopher Pieczonka. A scholar is included among the top collaborators of Christopher Pieczonka based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Christopher Pieczonka. Christopher Pieczonka is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Shore, Neal D., Murilo Luz, Ugo De Giorgi, et al.. (2025). Improved Survival with Enzalutamide in Biochemically Recurrent Prostate Cancer. New England Journal of Medicine. 394(6). 563–575. 1 indexed citations
2.
Daneshmand, Siamak, Christopher Pieczonka, Giuseppe Simone, et al.. (2025). SAFETY AND TOLERABILITY OF TAR-200 MONOTHERAPY IN PATIENTS WITH BACILLUS CALMETTE–GUÉRIN (BCG)-UNRESPONSIVE HIGH-RISK NON–MUSCLE-INVASIVE BLADDER CANCER (HR NMIBC) IN SUNRISE-1. Urologic Oncology Seminars and Original Investigations. 43(3). 55–55.
3.
Antonarakis, Emmanuel S., Sumit K. Subudhi, Christopher Pieczonka, et al.. (2023). Combination Treatment with Sipuleucel-T and Abiraterone Acetate or Enzalutamide for Metastatic Castration-Resistant Prostate Cancer: STAMP and STRIDE Trials. Clinical Cancer Research. 29(13). 2426–2434. 10 indexed citations
4.
Shore, Neal D., Christopher Pieczonka, Ralph J. Henderson, et al.. (2023). Development and evaluation of the MiCheck® Prostate test for clinically significant prostate cancer. Urologic Oncology Seminars and Original Investigations. 41(11). 454.e9–454.e16. 2 indexed citations
5.
Freedland, Stephen J., Murilo Luz, Ugo De Giorgi, et al.. (2023). Improved Outcomes with Enzalutamide in Biochemically Recurrent Prostate Cancer. New England Journal of Medicine. 389(16). 1453–1465. 114 indexed citations breakdown →
6.
Shen, John, Simon Chowdhury, Neeraj Agarwal, et al.. (2023). Apalutamide efficacy, safety and wellbeing in older patients with advanced prostate cancer from Phase 3 randomised clinical studies TITAN and SPARTAN. British Journal of Cancer. 130(1). 73–81. 8 indexed citations
7.
Yu, Evan Y., Christopher Pieczonka, Hiroyoshi Suzuki, et al.. (2023). Darolutamide observational (DAROL) study in patients with nonmetastatic castration-resistant prostate cancer: Second interim analysis.. Journal of Clinical Oncology. 41(16_suppl). e17095–e17095. 1 indexed citations
8.
Freedland, Stephen J., Martin Gleave, Antti Rannikko, et al.. (2023). 1766MO Health-related quality of life (HRQoL) in nonmetastatic hormone-sensitive prostate cancer (nmHSPC) patients (pts) with high-risk biochemical recurrence (BCR) from the EMBARK study. Annals of Oncology. 34. S955–S955. 1 indexed citations
9.
Markowski, Mark C., Ronald Tutrone, Christopher Pieczonka, et al.. (2022). A Phase Ib/II Study of Sabizabulin, a Novel Oral Cytoskeleton Disruptor, in Men with Metastatic Castration-resistant Prostate Cancer with Progression on an Androgen Receptor–targeting Agent. Clinical Cancer Research. 28(13). 2789–2795. 28 indexed citations
10.
Markowski, Mark C., Ronald Tutrone, Mario A. Eisenberger, et al.. (2021). VERU-111, an oral cytoskeleton disruptor, to treat men with metastatic castration-resistant prostate cancer (mCRPC) who failed an androgen receptor targeting agent.. Journal of Clinical Oncology. 39(15_suppl). 5056–5056. 1 indexed citations
11.
Markowski, Mark C., Mario A. Eisenberger, Ronald Tutrone, et al.. (2021). Clinical study of VERU-111, an oral cytoskeletal disruptor, in metastatic castration-resistant prostate cancer (mCRPC) who failed an androgen receptor targeting agent.. Journal of Clinical Oncology. 39(6_suppl). 131–131. 4 indexed citations
12.
Shore, Neal D., David Cahn, Christopher Pieczonka, et al.. (2021). PD13-10 UNIVERSAL GERMLINE TESTING OF PROSTATE CANCER PATIENTS: ARE GENETIC TESTING GUIDELINES AN IMPEDIMENT TO PRECISION THERAPY?. The Journal of Urology. 206(Supplement 3). 1 indexed citations
13.
Shore, Neal D., Christopher Pieczonka, Ralph J. Henderson, et al.. (2020). Development and evaluation of the MiCheck test for aggressive prostate cancer. Urologic Oncology Seminars and Original Investigations. 38(8). 683.e11–683.e18. 4 indexed citations
14.
Ross, Ashley E., Andrew J. Armstrong, Christopher Pieczonka, et al.. (2020). A comparison of sipuleucel-T (sip-T) product parameters from two phase III studies: PROVENT in active surveillance prostate cancer and IMPACT in metastatic castrate-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology. 38(6_suppl). 321–321. 6 indexed citations
15.
Shore, Neal D., et al.. (2019). MiCheck performance: Comparator trial of MiCheck with PHI, % free PSA and PSA—The impact on decision making for prostate biopsy.. Journal of Clinical Oncology. 37(7_suppl). 199–199.
16.
Karsh, Lawrence I., Christopher Pieczonka, Philip J. Aliotta, et al.. (2017). Absorbable Hydrogel Spacer Use in Prostate Radiotherapy: A Comprehensive Review of Phase 3 Clinical Trial Published Data. Urology. 115. 39–44. 82 indexed citations
17.
Dearnaley, David P., Daniel R. Saltzstein, John E. Sylvester, et al.. (2016). Neo/adjuvant ADT to EBRT: Randomized phase 2 trial of the oral GnRH antagonist, TAK-385 (relugolix, RGX) and degarelix (DGX) in patients (pts) with prostate cancer (PC). Annals of Oncology. 27. vi249–vi249. 7 indexed citations
18.
19.
Drake, Charles G., David I. Quinn, Robert Dreicer, et al.. (2015). Immune response from STRIDE, a randomized, Phase II, open-label study of sipuleucel-T (sip-T) with concurrent vs sequential enzalutamide (enz) administration in metastatic castration-resistant prostate cancer (mCRPC). Journal for ImmunoTherapy of Cancer. 3(Suppl 2). P145–P145. 2 indexed citations
20.
Pieczonka, Christopher, Neil Mariados, John E. Sylvester, et al.. (2015). Hydrogel Spacer Application Technique, Patient Tolerance and Impact on Prostate Intensity Modulated Radiation Therapy: Results from a Prospective, Multicenter, Pivotal Randomized Controlled Trial. Urology Practice. 3(2). 141–146. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by F. Gómez-Veiga Breakdown of academic impact, for papers by A. De La Taille Breakdown of academic impact, for papers by P. Cathcart Breakdown of academic impact, for papers by Roger Paul Breakdown of academic impact, for papers by Peter Hammerer Breakdown of academic impact, for papers by Henriette Lindberg Breakdown of academic impact, for papers by Brian Chon Breakdown of academic impact, for papers by Samuel Huang Breakdown of academic impact, for papers by Se Joong Kim Breakdown of academic impact, for papers by Muhammad Bulbul
Rankless by CCL
2026